Skip to main content
. Author manuscript; available in PMC: 2024 Apr 1.
Published in final edited form as: Curr Neurol Neurosci Rep. 2023 Mar 7;23(4):185–199. doi: 10.1007/s11910-023-01257-3

Table 2.

Molecular-Based Risk Stratification of pLGG [7]

Risk group Alteration type Outcomes
Low Gene fusions (BRAF-KIAA1549, FGFR1-TACC1)
Germline NF1 mutations		 10-year PFS of 67% and OS of 98%
20-year PFS and OS of 58% and 96%, respectively. [7]
Intermediate BRAF p.V600E without CDKN2A deletion, FGFR1 SNV or MET mutations
Co-occur with other alterations		 10-year PFS and OS of 35% and 90%
20-year PFS of 27% and 20-year OS of 81%, respectively. [7]
High H3.3 p.K27M, or BRAF p.V600E with CDKN2A deletion 10-year PFS and OS of 0% and 35%
10-year PFS and OS of 0% and 60%, respectively. [7]